6.65
Liminatus Pharma Inc Borsa (LIMN) Ultime notizie
Liminatus Pharma (NASDAQ:LIMN) Upgraded at Wall Street Zen - Defense World
Liminatus Pharma appoints Philip Lemons and Richard Baek to board of directors - Investing.com
Liminatus Pharma Expands Board with Two New Directors - TipRanks
Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) Stock Quote - FinancialContent
Liminatus Pharma Stock Soars 18.58% on Rebranding - AInvest
Liminatus Pharma Stock Soars 14.97% on Healthcare Sector Optimism - AInvest
Medicus Pharma Soars 10.95% on Acquisition News - AInvest
Liminatus Pharma's Pancreatic Cancer Diagnostic Consortium: A Strategic Pivot for Market Leadership? - AInvest
Liminatus Pharma sees stock surge on pancreatic cancer diagnostic kit collaboration - grafa.com
Liminatus Pharma Forms Consortium To Advance Diagnostic Kit For Early Pancreatic Cancer Detection - MarketScreener
Liminatus Pharma Warrant Holder Alleges Blocked Share Purchases - Bloomberg Law News
Liminatus Pharma forms consortium for pancreatic cancer diagnostic kit By Investing.com - Investing.com UK
Liminatus Pharma Forms R&D Consortium for Cancer Diagnostics - TipRanks
Liminatus Pharma Stock Soars 14.49% on 10K Filing - AInvest
Klotho Neurosciences Surges: What’s Driving the Gains? - timothysykes.com
Liminatus Pharma files to sell 6.9M shares of common stock - MSN
Liminatus Pharma Stock Soars 29.36% on Nasdaq Listing - AInvest
Carnival Posts Better-Than-Expected Earnings, Joins… - inkl
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Is Liminatus Pharma Inc (LIMN) Up 83%? Unpacking the Surge - Wealth Daily
KH Group's investment in US biotech Liminatus Pharma halves in one day - Chosun Biz
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Liminatus Pharma Plunges 12.06% Despite Regulatory Compliance - AInvest
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - MSN
Liminatus Pharma stock gains on regaining compliance with Nasdaq - MSN
Liminatus Pharma Plunges 15.24% on Volatility Pause - AInvest
Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday - Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings - Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase - Benzinga
Liminatus Pharma shares soar on Nasdaq compliance news By Investing.com - Investing.com Canada
Liminatus Pharma shares soar on Nasdaq compliance news - Investing.com Australia
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma Gains Compliance With Nasdaq Filing Requirements; Shares up Pre-Bell - marketscreener.com
Liminatus Pharma regains Nasdaq listing compliance - TipRanks
Liminatus Pharma Regains Nasdaq Compliance After Filing Delay - TipRanks
Liminatus Pharma Delays Quarterly Report Filing - TipRanks
Liminatus Pharma’s Merger with Iris Acquisition Corp. - Global Legal Chronicle
Iris Acquisition, Liminatus Pharma Sign SPAC Merger Deal - marketscreener.com
LIMN Stock Price and Chart — NASDAQ:LIMN - TradingView
Iris Acquisition Corp confirms delisting and shareholder vote outcomes - Investing.com
Iris Acquisition Corp announces preliminary proxy statement - Investing.com
Iris Acquisition Corp announces business combination - Investing.com
Iris Acquisition Corp announces business combination with Liminatus Pharma - Investing.com
New company Liminatus Pharma Inc to develop three cancer treatments - Labiotech.eu
A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47 - Endpoints News
Liminatus Pharma and Iris Acquisition to Combine in $334M Deal - The SPAC Conference
Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments - Business Wire
Holland & Knight Partner Seth Belzley Ranked Among Denver’s Outstanding "40 Under 40" Business Professionals - Holland & Knight
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):